Day: December 22, 2025
Samsung Biologics will acquire a drug manufacturing facility in the United States from GlaxoSmithKline (GSK) for $280 million, marking its first production foothold in the U.S. The move aims to enhance supply chain resilience amid rising biopharmaceutical trade barriers and tariff pressures from the United States, Azernews reports, citing Korean media.
Categories
跨境电商Tiktok 怎么做? – 知乎
Categories
